SEC Comment Letter 0000000000-23-009515 to Ambrx Biopharma, Inc. (CIK 0001990550)
Ambrx Biopharma, Inc. (CIK 0001990550)
Date: Aug. 29, 2023 · CIK: 0001990550 · Accession: 0000000000-23-009515
AI Filing Summary & Sentiment
File numbers found in text: 333-274230
Letter
United States securities and exchange commission logo August 29, 2023 Daniel J. O'Connor President and Chief Executive Officer New Ambrx Biopharma Inc. 10975 North Torrey Pines Road La Jolla, California 92037 Re:New Ambrx Biopharma Inc. Registration Statement on Form S-4 Filed August 25, 2023 File No. 333-274230 Dear Daniel J. O'Connor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Raymond Bogenrief, Esq.
Show Raw Text
United States securities and exchange commission logo
August 29, 2023
Daniel J. O'Connor
President and Chief Executive Officer
New Ambrx Biopharma Inc.
10975 North Torrey Pines Road
La Jolla, California 92037
Re:New Ambrx Biopharma Inc.
Registration Statement on Form S-4
Filed August 25, 2023
File No. 333-274230
Dear Daniel J. O'Connor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Raymond Bogenrief, Esq.